Covestor’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-228
| Closed | -$9K | – | 2467 |
|
|
2026
Q1 | $9K | Sell |
228
-191
| -46% | -$4.12K | 0.01% | 1443 |
|
|
2025
Q4 | $11K | Sell |
419
-3,669
| -90% | -$86.1K | 0.01% | 1509 |
|
|
2025
Q3 | $93K | Sell |
4,088
-512
| -11% | -$11.9K | 0.05% | 609 |
|
|
2025
Q2 | $80K | Buy |
4,600
+605
| +15% | +$11.2K | 0.05% | 672 |
|
|
2025
Q1 | $87K | Buy |
3,995
+3
| +0.1% | +$83 | 0.06% | 570 |
|
|
2024
Q4 | $127K | Buy |
3,992
+3,784
| +1,819% | +$114K | 0.08% | 366 |
|
|
2024
Q3 | $6K | Buy |
208
+1
| +0.5% | +$37 | ﹤0.01% | 1704 |
|
|
2024
Q2 | $8K | Buy |
207
+1
| +0.5% | +$45 | 0.01% | 1653 |
|
|
2024
Q1 | $12K | Sell |
206
-1
| -0.5% | -$64 | 0.01% | 1419 |
|
|
2023
Q4 | $12K | Sell |
207
-590
| -74% | -$29.9K | 0.01% | 1410 |
|
|
2023
Q3 | $30K | Buy |
797
+677
| +564% | +$29.7K | 0.02% | 974 |
|
|
2023
Q2 | $11K | Sell |
120
-49
| -29% | -$4.23K | 0.01% | 1377 |
|
|
2023
Q1 | $11K | Hold |
169
| – | – | 0.01% | 1250 |
|
|
2022
Q4 | $9K | Sell |
169
-8
| -5% | -$424 | 0.01% | 1356 |
|
|
2022
Q3 | $12K | Sell |
177
-98
| -36% | -$5.8K | 0.01% | 1176 |
|
|
2022
Q2 | $12K | Sell |
275
-1
| -0.4% | -$46 | 0.01% | 1136 |
|
|
2022
Q1 | $14K | Buy |
276
+257
| +1,353% | +$11.3K | 0.01% | 1175 |
|
|
2021
Q4 | $1K | Buy |
+19
| New | +$748 | ﹤0.01% | 1625 |
|
Other funds holding APLS
Covestor's APLS Position: Q2 2026 in Review
Covestor sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 228 shares — an estimated $9K sold.
Covestor first reported a position in APLS in Q4 2021 and held it in 18 quarters. The position peaked at $127K in Q4 2024. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Covestor reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Covestor sold 228 Apellis Pharmaceuticals shares in Q2 2026, an estimated $9K.
- Covestor first reported a position in Apellis Pharmaceuticals in Q4 2021 and held it in 18 quarters.
- Covestor's Apellis Pharmaceuticals position peaked at $127K in Q4 2024.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.